Skip to main content
Delfa

← All trials/NCT03002675

exe01

UnknownPhase 4

Exenatide and Brown Adipose Tissue

The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men

Lead sponsor

Ingrid Jazet

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Estimated enrollment

24

Study population

Healthy volunteers

Eligibility highlights

•BMI 18-25•Male

Primary endpoint

•Effect of exenatide on BAT activity

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03002675
Org study IDP16.078

Timeline

Milestones

Study first posted2016-12-26estimated
Last update posted2016-12-26estimated
Study start2016-08 (month precision)
Primary completion2018-06estimated (month precision)

Assets

Investigational agents

Exenatide

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age20 Years
Maximum age30 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•Dutch South Asian or white Caucasian male, 20-30 years
•BMI ≥ 18 and ≤ 25 kg/m2
•Good general health

Exclusion criteria

•BMI > 25 kg/m2 or < 18 kg/m2
•Use of medication known to influence glucose and/or lipid metabolism or brown fat activity (e.g. beta blockers)
•Any significant chronic disease
•Renal, hepatic or endocrine disease
•Smoking
•Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study
•Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year
•Contraindications for undergoing an MRI scan:
•Presence of non-MR safe metal implants or objects in the body.
•Pacemaker, neurostimulator, hydrocephalus pump, drug pump, non-removable hearing aid, large recent tattoos.
•Claustrophobia
•Tinnitus or hyperacusis

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint/low confidence

Visualisation of BAT as measured with MRI scan compared to FDG-PET CT

Time frame:End of the study, up to 21 months

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

The effect of exenatide on BAT activity and energy expenditure in healthy young South Asian compared to white Caucasian men

Time frame:End of the study, up to 21 months

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.